Australia's most trusted
source of pharma news
Tuesday, 01 July 2025
Posted 28 October 2024 AM
The conduct of Alzheimer's researchers in clinical trials has come under question, with revelations the results of genetic testing were withheld from participants which throws doubt on whether their consent was truly informed.
An article in the New York Times (NYT) raises the issue of informed consent of the participants in trials testing two Alzheimer's drugs, Biogen and Eisai's Leqembi and Eli Lilly's Kisunla.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.